Jinzi Wu
Vorstandsvorsitzender bei ASCLETIS PHARMA INC.
Vermögen: 92 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Judy Hejingdao Wu | F | 50 |
Ascletis Pharmaceuticals Co., Ltd.
Ascletis BioScience Co., Ltd.
Gannex LLC
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | 10 Jahre |
| George Kemble | M | 63 | 13 Jahre | |
| Merdad Parsey | M | 61 | 14 Jahre | |
| David Happel | M | 62 | 2 Jahre | |
| Cheng Li | M | 67 |
Nanjing University
| 46 Jahre |
| Beth Seidenberg | M | 67 | 17 Jahre | |
| Jiong Gu | M | 51 | 6 Jahre | |
| Lin Hua | F | 50 | 6 Jahre | |
| Yizhen Wei | M | 49 | 6 Jahre | |
| Joshua Zhongbao | M | - | 6 Jahre | |
| Elizabeth Rozek | F | 53 | 1 Jahre | |
| Zhi Ming Cheng | M | 62 |
Nanjing University
| 42 Jahre |
| Richard Rodgers | M | 57 | 9 Jahre | |
| Victor Shi | M | - |
The BayHelix Group
| - |
| Elizabeth Grammer | F | 60 | 3 Jahre | |
| Guo-Liang Yu | M | 62 |
The BayHelix Group
| - |
| John Gargiulo | M | - | 2 Jahre | |
| Yi You Chen | M | - |
The BayHelix Group
| - |
| Yan Yuemei | F | - | - | |
| Duncan Jodrell | M | - | - | |
| Johann Bono | M | - | - | |
| Ursula Matulonis | F | - | - | |
| Yun Zhang | F | 40 |
The BayHelix Group
| - |
| Yuan Hua Ding | M | 61 |
The BayHelix Group
| - |
| Handan He | M | - | 5 Jahre | |
| Zhengqing Li | M | - | 5 Jahre | |
| Jian Fan | M | 67 |
Nanjing University
| 41 Jahre |
| Eduardo Bruno Martins | M | 61 | 3 Jahre | |
| Marietta Wu | M | 56 |
The BayHelix Group
| - |
| Wei Fu | M | 42 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
| Ming Guo | M | 67 |
The BayHelix Group
| - |
| Yi Ning Zhao | M | 53 |
The BayHelix Group
| 13 Jahre |
| Anne-Marie O'Farrell | M | - | 11 Jahre | |
| James Xue | M | 55 |
The BayHelix Group
| - |
| Ming Fai Chung | M | 45 | 2 Jahre | |
| Gaeton Biscardi | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Steven Gillis | M | 71 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 13 Jahre |
| Joseph Oriti | M | 44 | - | |
| Philippe Calais | M | 65 |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 Jahre |
| Giancarlo Mocchi | M | 84 | 3 Jahre | |
| Anthony Rimac | M | 60 | 1 Jahre | |
| Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 Jahre |
| Ji Shun Liu | M | 66 |
Nanjing University
| 9 Jahre |
| Rolf M. Zinkernagel | M | 80 | 15 Jahre | |
| Pierre Landolt | M | 77 | 22 Jahre | |
| Ulrich Lehner | M | 78 | 13 Jahre | |
| Hai Sang | M | 67 |
Nanjing University
| 6 Jahre |
| Jin Xing Qi | M | 62 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
| Edward V. Fritzky | M | 73 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 8 Jahre |
| Peter Atadja | M | 64 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 24 Jahre |
| Christine L. Salvesen | F | - |
University of Arizona
| 6 Jahre |
| Peter Kornicker | M | - | 20 Jahre | |
| Bosheng Zhou | M | 59 |
Nanjing University
| 7 Jahre |
| Zhen Hai Liang | M | 59 |
Nanjing University
| 7 Jahre |
| Haichuan Qian | M | - |
Nanjing University
| 7 Jahre |
| Mathew Cherian | M | 59 | 30 Jahre | |
| Long Quan Pan | M | 60 |
Nanjing University
| 6 Jahre |
| Run Yu | M | 68 |
Nanjing University
| 18 Jahre |
| Bradley Mitchell | M | - |
University of Arizona
| 7 Jahre |
| Wei Dong Li | M | 56 |
Nanjing University
| 6 Jahre |
| Dong Xiao Zhang | M | 58 |
University of Arizona
| 3 Jahre |
| Daniel McEvers Mahoney | M | - |
University of Arizona
| 8 Jahre |
| Nicole T. Sweetland | M | - |
University of Arizona
| 4 Jahre |
| Stephen G. Sudovar | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 Jahre |
| Peter Burckhardt | M | - | - | |
| Subhash Raghunath Gupte | M | 85 | 25 Jahre | |
| Ayani Kurussi Ravi Nedungadi | M | 65 | - | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 Jahre |
| Paulo Costa | M | 73 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 6 Jahre |
| James Young | M | 71 | 13 Jahre | |
| Gordon Ringold | M | 73 | 14 Jahre | |
| Wayne P. Yetter | M | 78 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | - |
| Chad W. Souvignier | M | - |
University of Arizona
| 5 Jahre |
| Alexandre F. Jetzer-Chung | M | 83 | 15 Jahre | |
| Daniel Vasella | M | 70 | 17 Jahre | |
| Bonabes-Olivier de Rougé | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 Jahre |
| Hai Wen He | F | 54 |
University of Arizona
| 2 Jahre |
| Shawn Davis | M | - |
University of Arizona
| 4 Jahre |
| Jason P. Ley | M | - |
University of Arizona
| 3 Jahre |
| Natalie Burkart | F | - |
University of Arizona
| 4 Jahre |
| Adam Brooks | M | - |
University of Arizona
| 4 Jahre |
| Matthew Shane | M | - |
University of Arizona
| 4 Jahre |
| Bart Patterson | M | - |
University of Arizona
| 4 Jahre |
| Peter W. Rutti | M | - |
University of Arizona
| 4 Jahre |
| Robert Ferris | M | 52 |
University of Arizona
| 3 Jahre |
| Justin Keith Gard | M | - |
University of Arizona
| 5 Jahre |
| Michael Daniel Roth | M | - |
University of Arizona
| 4 Jahre |
| Sri Nagarajan | M | - |
University of Arizona
| 2 Jahre |
| Gregory Gemson | M | - |
University of Arizona
| 4 Jahre |
| Jesse M. Wellner | M | - |
University of Arizona
| 4 Jahre |
| Brandon Nagler | M | - |
University of Arizona
| 4 Jahre |
| Aaron Todd Switz | M | - |
University of Arizona
| 4 Jahre |
| George Sohos | M | 57 |
University of Arizona
| 3 Jahre |
| Courtney J. Hehre | F | - |
University of Arizona
| 4 Jahre |
| Jonathan A. Firestein | M | - |
University of Arizona
| 4 Jahre |
| Bryce Hancock | M | - |
University of Arizona
| 4 Jahre |
| Michael Chen | M | 54 |
University of Arizona
| 2 Jahre |
| Stephen Beaver | M | 52 |
University of Arizona
| 4 Jahre |
| Jason Rowley | M | - |
University of Arizona
| 4 Jahre |
| Nick Ogurtsov | M | 46 |
University of Arizona
| 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 63 | 63,00% |
| China | 14 | 14,00% |
| Cayman Islands | 10 | 10,00% |
| Schweiz | 8 | 8,00% |
| Kanada | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
